{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:30:56Z","timestamp":1707525056143},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,21]]},"DOI":"10.7759\/cureus.40753","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T18:32:06Z","timestamp":1687372326000},"source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular Remodeling in Chronic Mineralocorticoid Excess"],"prefix":"10.7759","author":[{"given":"Pradnya Brijmohan","family":"Bhattad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mazen","family":"Roumia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.09.057","article-title":"Primary aldosteronism: JACC state-of-the-art review","volume":"74","author":"Rossi GP","year":"2019","unstructured":"Rossi GP. Primary aldosteronism: JACC state-of-the-art review. J Am Coll Cardiol. 2019, 74:2799-811. 10.1016\/j.jacc.2019.09.057","journal-title":"J Am Coll Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-019-1185-x","article-title":"Primary aldosteronism: Cardiovascular outcomes pre- and post-treatment","volume":"21","author":"Hundemer GL","year":"2019","unstructured":"Hundemer GL. Primary aldosteronism: Cardiovascular outcomes pre- and post-treatment. Curr Cardiol Rep. 2019, 21:93. 10.1007\/s11886-019-1185-x","journal-title":"Curr Cardiol Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2019.08.002","article-title":"Primary aldosteronism diagnosis and management: A clinical approach","volume":"48","author":"Hundemer GL","year":"2019","unstructured":"Hundemer GL, Vaidya A. Primary aldosteronism diagnosis and management: A clinical approach. Endocrinol Metab Clin North Am. 2019, 48:681-700. 10.1016\/j.ecl.2019.08.002","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12831","article-title":"Diagnosis and treatment of primary aldosteronism: practical clinical perspectives","volume":"285","author":"Young WF Jr","year":"2019","unstructured":"Young WF Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2019, 285:126-48. 10.1111\/joim.12831","journal-title":"J Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00261.2016","article-title":"Hyperaldosteronism induces left atrial systolic and diastolic dysfunction","volume":"311","author":"Reil JC","year":"2016","unstructured":"Reil JC, Tauchnitz M, Tian Q, et al.. Hyperaldosteronism induces left atrial systolic and diastolic dysfunction. Am J Physiol Heart Circ Physiol. 2016, 311:H1014-23. 10.1152\/ajpheart.00261.2016","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-008-0092-0","article-title":"Resistant hypertension and hyperaldosteronism","volume":"10","author":"Gonzaga CC","year":"2008","unstructured":"Gonzaga CC, Calhoun DA. Resistant hypertension and hyperaldosteronism. Curr Hypertens Rep. 2008, 10:496-503. 10.1007\/s11906-008-0092-0","journal-title":"Curr Hypertens Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2116","article-title":"Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry","volume":"94","author":"Born-Frontsberg E","year":"2009","unstructured":"Born-Frontsberg E, Reincke M, Rump LC, et al.. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab. 2009, 94:1125-30. 10.1210\/jc.2008-2116","journal-title":"J Clin Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000619","article-title":"Circulating tissue inhibitor of matrix metalloproteinase-1 is associated with aldosterone-induced diastolic dysfunction","volume":"33","author":"Hung CS","year":"2015","unstructured":"Hung CS, Chou CH, Wu XM, et al.. Circulating tissue inhibitor of matrix metalloproteinase-1 is associated with aldosterone-induced diastolic dysfunction. J Hypertens. 2015, 33:1922-30; discussion 1930. 10.1097\/HJH.0000000000000619","journal-title":"J Hypertens"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1565055","article-title":"Aldosterone and left ventricular remodeling","volume":"47","author":"Catena C","year":"2015","unstructured":"Catena C, Colussi G, Brosolo G, Novello M, Sechi LA. Aldosterone and left ventricular remodeling. Horm Metab Res. 2015, 47:981-6. 10.1055\/s-0035-1565055","journal-title":"Horm Metab Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2016.06.015","article-title":"Primary aldosteronism: Diagnosis and management","volume":"352","author":"Gyamlani G","year":"2016","unstructured":"Gyamlani G, Headley CM, Naseer A, Valaulikar GS, Geraci SA. Primary aldosteronism: Diagnosis and management. Am J Med Sci. 2016, 352:391-8. 10.1016\/j.amjms.2016.06.015","journal-title":"Am J Med Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.suc.2019.04.010","article-title":"Evaluation and management of primary hyperaldosteronism","volume":"99","author":"Lee FT","year":"2019","unstructured":"Lee FT, Elaraj D. Evaluation and management of primary hyperaldosteronism. Surg Clin North Am. 2019, 99:731-45. 10.1016\/j.suc.2019.04.010","journal-title":"Surg Clin North Am"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042711-135929","article-title":"Hyperaldosteronism as a common cause of resistant hypertension","volume":"64","author":"Calhoun DA","year":"2013","unstructured":"Calhoun DA. Hyperaldosteronism as a common cause of resistant hypertension. Annu Rev Med. 2013, 64:233-47. 10.1146\/annurev-med-042711-135929","journal-title":"Annu Rev Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: Case detection, diagnosis, and treatment: An endocrine society clinical practice guideline","volume":"101","author":"Funder JW","year":"2016","unstructured":"Funder JW, Carey RM, Mantero F, et al.. The management of primary aldosteronism: Case detection, diagnosis, and treatment: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016, 101:1889-916. 10.1210\/jc.2015-4061","journal-title":"J Clin Endocrinol Metab"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1590\/2359-3997000000274","article-title":"Diagnosis and management of primary aldosteronism","volume":"61","author":"Vilela LA","year":"2017","unstructured":"Vilela LA, Almeida MQ. Diagnosis and management of primary aldosteronism. Arch Endocrinol Metab. 2017, 61:305-12. 10.1590\/2359-3997000000274","journal-title":"Arch Endocrinol Metab"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012410","article-title":"Incidental congestive heart failure in patients with aldosterone-producing adenomas","volume":"8","author":"Huang WC","year":"2019","unstructured":"Huang WC, Chen YY, Lin YH, et al.. Incidental congestive heart failure in patients with aldosterone-producing adenomas. J Am Heart Assoc. 2019, 8:e012410. 10.1161\/JAHA.119.012410","journal-title":"J Am Heart Assoc"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/98697-cardiovascular-remodeling-in-chronic-mineralocorticoid-excess","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:04:20Z","timestamp":1707509060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/98697-cardiovascular-remodeling-in-chronic-mineralocorticoid-excess"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.40753","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,21]]}}}